

Viral Safety Reloaded - the Finalized ICH Q5A (R2)

26-27 June 2024

Agenda

Wedne	esday, 26 June 2024	
9:00	Welcome and Introduction	Falk Klar, PDA Europe
	Welcome from the Co-Chairs	Andy Bailey, ViruSure Sean O'Donnell, Eli Lilly and Company
Opening Plenary		Moderator: Andy Bailey, ViruSure
	Keynote: A Patient Perspective on Hemophilia	Invited Speaker
	Updates on ICH Q5A (R2)	Paul Ehrlich Institut
	Q&A, Discussion	
10:45	Coffee Break, Poster Session & Exhibition	
Session 1. Vital Salety of Advanced Therapies		Moderator: Alison Armstrong, Merck KGaA
	Viral Safety Strategy for Adeno-Associated Virus Gene Therapy Products	Alexion
	The Design, Development, and Validation of Platform Methodology for Replication Competent Adeno Associated Virus	Charles River
	Virus Safety of Xenotransplantation	Institute of Virology, Freie Universität Berlin
	Q&A, Discussion	
12:35	Lunch Break, Poster Session & Exhibition	



Viral Safety Reloaded - the Finalized ICH Q5A (R2)

LIVE Guided Poster Walk	Moderator: Sebastian
Engage with our Poster Presenters in our Exhibition Hall	Teitz, Consultancy
Interactive Questionnaire Session	Moderator: David Cetlin, Cygnus
Session 2: Virus Testing	
Next Generation Sequencing Implementation Strategies for Adventitious Virus Detection in Viral Vaccines and Biologics	Johnson and Johnson
Approaches for Accelerated Adventitious Virus Testing and Strategies for Rapid Differentiation of Replicating Viral Infections from Inert Viral Sequences in Viral Vector Vaccines and Raw Materials	IDT Biologika
Transcriptomic Next Generation Sequencing Assay of Cells: Detection Range and Sensibility For The 71 Human, Porcine, and Bovine Rodent Viruses to be Detected by The MAP/RAP/HAP, 9CFR, and PCR Regulatory Assays	PathoQuest
Q&A, Discussion	
Coffee Break, Poster Session & Exhibition	
Session 3: Novel Approaches and Digitization	
A Deep-Learning Classifier of Adventitious Agents	MilliporeSigma
Automation of Virus Detection Assays Used in Virus Clearance Studies: From Liquid Handling to the Use of Machine-learning and Artificial Intelligence in Analyzing Cytopathic Effects	CSL Behring
Adventitious Agent Testing for Minute Virus of Mice: How Much Do We Really Know?	Takeda
Q&A, Discussion	
End of Conference Day 1 & Networking Event	
	Next Generation Sequencing Implementation Strategies for Adventitious Virus Detection in Viral Vaccines and Biologics Approaches for Accelerated Adventitious Virus Testing and Strategies for Rapid Differentiation of Replicating Viral Infections from Inert Viral Sequences in Viral Vector Vaccines and Raw Materials Transcriptomic Next Generation Sequencing Assay of Cells: Detection Range and Sensibility For The 71 Human, Porcine, and Bovine Rodent Viruses to be Detected by The MAP/RAP/HAP, 9CFR, and PCR Regulatory Assays Q&A, Discussion Coffee Break, Poster Session & Exhibition vel Approaches and Digitization A Deep-Learning Classifier of Adventitious Agents Automation of Virus Detection Assays Used in Virus Clearance Studies: From Liquid Handling to the Use of Machine-learning and Artificial Intelligence in Analyzing Cytopathic Effects Adventitious Agent Testing for Minute Virus of Mice: How Much Do We Really Know? Q&A, Discussion



Viral Safety Reloaded - the Finalized ICH Q5A (R2)

Thursday, 27 June 2024			
9:00	Welcome to Day 2	Andy Bailey, ViruSure Sean O'Donnell, Eli Lilly and Company	
Session 4: Virus Inactivation and Virus Removal		Moderator: Remo Leisi, CSL Behring Co-Moderator: Tomoko Hongo-Hirasaki, Asahi Kasei	
	Inactivation of Hepatitis E Virus by Dry-Heat Treatment	Octapharma Biopharmaceuticals	
	Viral Clearance Validation of Continuous Virus Filtration: Adapting Alternate Approaches to a New Manufacturing Paradigm	Asahi Kasei	
	Virus Safety of Medical Devices Utilizing Animal Materials	TÜV SÜD	
	Q&A, Discussion		
10:15	Coffee Break, Poster Session & Exhibition		
		Moderator: Simone Olgiati, Merck KGaA	
	Evaluation of Next Generation Sequencing Performance for in vitro Detection of Viruses in Biological Products	National Institute of Health Sciences	
	Head-to-Head Comparison of NGS with Vivo Animal Assays and In Vitro Cell Culture Assays for Adventitious Virus Detection	U.S. FDA	
	Advanced Virus Detection Interest Group Spiking Study 3 - Sensitivity of High-Throughput Sequencing (HTS) Transcriptomics Analysis for Detection of Adventitious Viruses in a Cell Substrate Background	GSK	
	Q&A, Discussion		



Viral Safety Reloaded - the Finalized ICH Q5A (R2)

26-27 June 2024			
12:00	Lunch Break, Poster Session & Exhibition		
	Interactive Questionnaire Session	Moderator: Sean O'Donnell, Eli Lilly and Company	
Session 6: Sustainability		Moderator: Sebastian Teitz, Consultancy	
	The Development of a Sustainable Alternative Detergent to Triton X-100	Amgen	
	Eco-Friendly Detergent Inactivation and Clearance for a Hybrid- Continuous Process for Biologics Manufacturing	Just-Evotec Biologics	
	Q&A, Discussion		
14:15	Coffee Break, Poster Session & Exhibition		
14:45	Passport Raffle via PDA Europe		
Closing Plenary		Moderator: Sean O'Donnell, Eli Lilly and Company	
	Center for Drug Evaluation and Research Updates on Viral Safety	U.S. FDA	
	Title to be Advised	Invited Speaker	
	Closing Panel Discussion Join our Discussion with Experts from the Academies, Industry, and Regulatory • US. FDA • Paul Ehrlich Institut • Freie Universität Berlin • Takeda		
	Co-Chairs Conference Summary	Andy Bailey, ViruSure Sean O'Donnell, Eli Lilly and Company	



Viral Safety Reloaded - the Finalized ICH Q5A (R2)

	Closing Remarks & Farewell	Falk Klar, PDA Europe
16:40	End of Conference	